---
schema_version: "secwatch.filing_event.v1"
accession: "0001534120-25-000013"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:38:34.508355+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Avalo completes Phase 2 LOTUS enrollment for AVTX-009; topline data mid-2026

## Summary
- Enrolled ~250 patients, exceeding the 222-patient target.
- Trial is randomized, double-blind, placebo-controlled with two AVTX-009 dose regimens.
- Primary endpoint is HiSCR75 at Week 16; topline results expected mid-2026.
- CEO Dr. Garry Neil cited strong investigator and patient engagement due to high unmet need.
- Trial identifier NCT06603077; details at clinicaltrials.gov or lotustrial.com.

## SEC filing metadata
- accession: 0001534120-25-000013
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000153412025000013/0001534120-25-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000153412025000013/avtx-20251029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001534120-25-000013
- JSON: https://secwatch.observer/filing/0001534120-25-000013.json
- Plain text: https://secwatch.observer/filing/0001534120-25-000013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.